Radioiodine for Hyperthyroidism Not Found to Be Associated With Incident Cancer Risk
In patients with hyperthyroidism, treatment with radioiodine is not associated with incident cancer in long-term follow-up.
Thyroid Cancer
Trends in Incidence of Thyroid Cancer Examined in United States
From 2009 to 2016, the incidence of thyroid cancer reached a plateau and possibly started to decline.
Radiation Exposure From CT Scans Linked to Thyroid Cancer
Exposure to medical radiation from computed tomography scans is associated with an increased risk for thyroid cancer and leukemia.
Active Surveillance Feasible for Papillary Thyroid Microcarcinomas
In healthy patients with papillary thyroid microcarcinomas, active surveillance may be a feasible and safe alternative to immediate surgery, according to study results published in The Journal of Clinical Endocrinology & Metabolism. There is controversy regarding optimal management of low-risk thyroid carcinomas, with active surveillance emerging as a potential alternative to surgery. However, there is…
The Different Pathways to Diagnosis and Treatment of Thyroid Microcarcinomas
The diagnostic pathway leading to diagnosis of thyroid microcarcinoma (tumor size ≤1 cm) is very different than that of larger thyroid tumors.
Annual Postoperative Ultrasound May Not Be Necessary in Low-Risk Thyroid Cancer
Serum tumor markers alone can provide reliable surveillance of patients who undergo total thyroidectomy for low- and intermediate-risk papillary thyroid carcinoma.
Entractinib, a Tumor Agnostic Therapy, Receives FDA Approval
Rozlytrek is a kinase inhibitor that selectively targets ROS1 and NTRK fusions.
Many Patients Perceive Lack of Choice in Receiving RAI for Thyroid Cancer
Many patients diagnosed with differentiated thyroid cancer perceive that they have no choice about receiving radioactive iodine.
Case Study: Tingling and Numbness After Thyroid Cancer Surgery
A woman who underwent total thyroidectomy with neck dissection experiences headaches, muscle spasms, and cramps.
Extranodal Extension May Indicate Intermediate Recurrence Risk in Papillary Thyroid Carcinoma
When the investigators included extranodal extension in the ATA’s current PTC risk stratification system, 32.8% of patients originally categorized as low risk with ≤5 positive lymph nodes were increased to intermediate risk.
